What is Claimed is:

1. A method for preparing a pharmaceutical composition, the method comprising:

preparing a first mixture by uniformly mixing 300 to 3600 parts by weight of a hydrophilic polymer, 300 to 3600 parts by weight of tricalcium phosphate, and 100 to 1800 parts by weight of a water-soluble dispersant, wherein the hydrophilic polymer is selected from the group consisting of a salt of alginatic acid, polyacrylic acid, gelatin, carboxymethyl cellulose (CMC), polyglutamatic acid (γ-PGA) , and wherein the water-soluble dispersant is selected from the group consisting of methyl cellulose (MC), carboxymethyl cellulose (CMC), hydroxyethyl cellulose (HEC) and hydroxypropyl methyl cellulose (HPMC);

preparing a second mixture by uniformly mixing 100 to 7200 parts by weight of a water-absorbing material, and 10 to 1800 parts by weight of a divalent cationic salt, wherein the water-absorbing material has high biocompatibility, moisture content and degradable property, wherein the water-absorbing material is selected from the group consisting of hyaluronic acid (HA), sodium hyaluronate, collagen, gelatin and polydextrose, and wherein the divalent cationic salt is selected from the group consisting of calcium chloride ($CaCl_2$), calcium carbonate ($CaCO_3$), barium chloride ($BaCl_2$), strontium chloride ($SrCl_2$) and magnesium chloride ($MgCl_2$);

preparing a precursor mixture by uniformly mixing a drug and the first mixture in water; and

uniformly mixing the second mixture and the precursor mixture.

2. The method of claim 1, wherein the tricalcium phosphate is α-phase tricalcium phosphate or β-phase tricalcium phosphate.

3. The method of claim 1, wherein the drug is an anti-inflammatory drug or an antibiotic.

4. The method of claim 3, wherein the anti-inflammatory drug is selected from the group consisting of adalimumab, certolizumab, etanercept, golimumab, abatacept, tocilizumab, rituximab and infliximab.

5. The method of claim 3, wherein the antibiotic is selected from the group consisting of gentamicin, vancomycin, mezlocillin, cloxacillin, methicillin, cefalothin, lincomycin, polymyxin E, bacitracin and fusidic acid.

6. A pharmaceutical composition prepared by the method of claim 1.

7. The pharmaceutical composition of claim 6, wherein the drug is an anti-inflammatory drug or an antibiotic.

8. The pharmaceutical composition of claim 7, wherein the anti-inflammatory drug is selected from the group consisting of adalimumab, certolizumab, etanercept, golimumab, abatacept, tocilizumab, rituximab and infliximab.

9. The pharmaceutical composition of claim 7, wherein the antibiotic is selected from the group consisting of gentamicin, vancomycin, mezlocillin, cloxacillin, methicillin, cefalothin, lincomycin, polymyxin E, bacitracin and fusidic acid.